Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1037-1044

  Humeniuk, Rita ^a,g   Menon, Lata G ^b,h   Mishra, Prasun J ^a,g   Gorlick, Richard ^c   Sowers, Rebecca ^c   Rode, Wojciech ^d   Pizzorno, Giuseppe ^e   Cheng, Yung Chi ^e   Kemeny, Nancy ^f   Bertino, Joseph R ^b   Banerjee, Debabrata ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; PHOSPHOTRANSFERASE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URIDINE PHOSPHATE KINASE; URIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; PRIORITY JOURNAL; RNA METABOLISM;

CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; NUCLEOSIDE-PHOSPHATE KINASE; RNA INTERFERENCE; URIDINE;

EID: 66849132243     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0716     Document Type: Conference Paper

References (32)

1. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006;13:668-676
2. Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin Oncol 1999;26:606-611 (Pubitemid 30013267)
3. Gorlick R, Banerjee D. Fluoropyrimidine resistance in colon cancer. Expert Rev Anticancer Ther 2002;2:409-416 (Pubitemid 34947117)
4. Biasco G, Derenzini E, Grazi G, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006;32:214-228
5. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006;1766:184-196 (Pubitemid 46321456)
6. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237 (Pubitemid 19114713)
7. Sommer H, Santi DV. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 1974;57:689-695
8. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-381 (Pubitemid 27020595)
9. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A 1997;94:1795-1799 (Pubitemid 27113915)
10. Fang F, Hoskins J, Butler JS. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 2004;24:10766-10776 (Pubitemid 39603133)
11. Sobrero AF, Aschele C, Guglielmi AP, et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993;85:1937-1944 (Pubitemid 23354033)
12. Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993;33:179-180 (Pubitemid 23325422)
13. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-2042 (Pubitemid 24356018)
14. Aschele C, Debernardis D, Bandelloni R, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002;13:1882-1892 (Pubitemid 36040777)
15. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-1864.
16. Hsu CH, Liou JY, Dutschman GE, Cheng YC. Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium. Mol Pharmacol 2005;67:806-814 (Pubitemid 40365328)
17. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 2000;87:189-198
18. Pasti C, Gallois-Montbrun S, Munier-Lehmann H, Veron M, Gilles AM, Deville-Bonne D. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur J Biochem 2003;270:1784-1790 (Pubitemid 36532537)
19. Vilpo JA, Vilpo LM. Nucleoside monophosphate kinase may be the key enzyme preventing salvage of DNA 5-methylcytosine. Mutat Res 1993;286:217-220 (Pubitemid 23103827)
20. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol Pharmacol 1999;56:562-569 (Pubitemid 29406883)
21. Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 2002;62:1624-1631 (Pubitemid 34408481)
22. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 1995;49:559-565
23. Beutler E. Red cell metabolism: a manual of biochemical methods. New York: Grunne and Stratton; 1984.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-408 (Pubitemid 34164012)
25. Wilkinson DS, Tlsty TD, Hanas RJ. The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 1975;35:3014-3020
26. Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res 2003;9:1235-1239 (Pubitemid 36418371)
27. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
28. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005;23:4545-4552 (Pubitemid 46196585)
29. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 2004;64:8167-8176 (Pubitemid 39491752)
30. Schmidt WM, Kalipciyan M, Dornstauder E, et al. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 2004;112:200-212 (Pubitemid 39244359)
31. Bravard A, Luccioni C, Muleris M, Lefrancois D, Dutrillaux B. Relationships between UMPK and PGD activities and deletions of chromosome 1p in colorectal cancers. Cancer Genet Cytogenet 1991;56:45-56.
32. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol Cancer Ther. In press, 2009.